Short answer
BridgeBio Pharma, Inc. (BBIO) filed its Q3 2025 10-Q quarterly report on Oct 29, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $121M (up 4318.0% year over year) with net income of −$183M.
Q3 2025 key financials · XBRL
- Revenue
- $121M
- +4318.0% YoY · +9.2% QoQ
- Net income
- −$183M
- −12.8% YoY · −0.5% QoQ
- Operating margin
- -120.3%
- EPS (diluted)
- −$0.95
- −9.2% YoY · +1.0% QoQ
Source: XBRL data from the BridgeBio Pharma, Inc. (BBIO) Q3 2025 10-Q on SEC EDGAR. USD.
BridgeBio Pharma, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: FDA’s 2025 increased scrutiny of DTC advertising, including untitled letter received for Attruby ad
- Updated operational risk: ongoing FDA staffing cuts and leadership departures causing review delays and regulatory uncertainties
- Regulatory risk: government shutdown on Oct 1, 2025 led to FDA furloughs, risking delays in IND reviews and patent approvals
- Operational risk: complete dependence on third-party manufacturers for commercial and clinical supply of Attruby, Beyonttra, and pipeline products
- Financial risk: reliance on single-source suppliers for drug substances, risking supply disruptions, price increases, and delayed development
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BridgeBio Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.